DoW Toxic Exposures Clinical Trial Award

Key facts

Copied from the official Grants.gov record. Last verified October 29, 2026.

Program name

DoW Toxic Exposures Clinical Trial Award

Issuing agency

Defense Health Agency Contracting Activity - DHACA (Department of Defense)

Opportunity number

HT942526TERPCTA

Funding type

Grant

Funding purpose

Science and Technology and other Research and Development

Status

Open (posted)

Application deadline

Closes November 19, 2026(21 days left)

Published award range

Not published by the agency

Estimated total program funding

$4,500,000

Expected number of awards

1

Cost sharing or match required

No

Eligible applicants (official categories)

• Unrestricted (open to any type of entity, subject to any clarification in Additional Information on Eligibility)

Relevant to

Businesses and NonprofitsHow we determined this: Grants.gov lists eligibility as Unrestricted.

Geographic restrictions

None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.

Assistance Listing (CFDA)

12.420

Official source

View on Grants.gov ↗

Application URL

www.grants.gov/search-results-detail/362302 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.

Source identifier

Grants.gov opportunity ID 362302 · Funding opportunity number HT942526TERPCTA

Posted

May 21, 2026 · Source last updated May 21, 2026

Last verified

October 29, 2026 (against Grants.gov)

Data completeness

83% of key fields published by the sourceNot published: published funding range, eligibility criteria text.

Record confidence

highVerified against the official source; key fields present; no open issues.

Description (from the official listing)

Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann

Agency contact

eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
help@eBRAP.org